De resultaten kunnen per persoon verschillen
pubmed.ncbi.nlm.nih.gov/37366315 UK regulatory status retatrutide is an unlicensed investigational compound supplied strictly for research, not human consumption, as of 2026.
Rybelsus patients lost between 2.5% and 4.1% of their body weight on average
Wanneer u de vergeten dosis binnen vijf dagen ontdekt, kunt u deze alsnog toedienen
With consistent use, you may begin to notice results within 1 to 3 months
This approval makes Eli Lillys oral GLP-1 receptor agonist, to be marketed as Foundayo, the second GLP-1 drug for weight loss available in pill form, after Wegovy, which gained approval in December 2025